Clene to Present at the Emerging Growth Conference

Clene (Nasdaq: CLNN) management will present a corporate update at the Emerging Growth Conference on January 21, 2026 at 3:10 p.m. ET.

Rhea-AI Summary

Clene (Nasdaq: CLNN) management will present a corporate update at the Emerging Growth Conference on January 21, 2026 at 3:10 p.m. ET. The presentation is virtual and will be webcast; live access is available via registration at the provided webcast link and from the Events section of the Clene website. A replay will be available after the event through the conference portal and the Emerging Growth YouTube channel. The conference hosts video webcasts in Eastern Time and targets individual and institutional investors, advisors, and analysts.

Argus Jan 16 session

-1.17% close to close Open Argus

Details

News Market Reaction – CLNN

On Jan 16, the day this news came out, CLNN closed 1.17% below the previous close.

Data tracked by StockTitan Argus for the Jan 16 session.

Key Figures

Conference date: January 21, 2026 Presentation time: 3:10 p.m. ET

Conference date

January 21, 2026

Emerging Growth Conference virtual corporate update

Presentation time

3:10 p.m. ET

Scheduled start time of Clene’s virtual presentation

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Clinical data update

   24h Move

   -19.0%

   Additional CNM-Au8 biomarker data and FDA Type C meeting in Q1 2026.

2. Jan 09

   Financing / offering

   24h Move

   +7.1%

   Registered direct offering of roughly $28M with warrant-linked tranches.

3. Dec 09

   Investor conference

   24h Move

   +6.3%

   Virtual Emerging Growth Conference corporate update on ALS and MS programs.

4. Dec 03

   Clinical data update

   24h Move

   -22.0%

   Statistically significant ALS biomarker results supporting accelerated approval plan.

5. Dec 02

   Program update event

   24h Move

   -3.1%

   Scheduled CNM-Au8 ALS program update webcast and investor call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

amyotrophic lateral sclerosis, als, multiple sclerosis, ms, +2 more

6 terms

amyotrophic lateral sclerosis medical

"to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

als medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

multiple sclerosis medical

"including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

ms medical

"amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced"

Multiple sclerosis is a chronic neurological disease in which the immune system damages the protective coating around nerve fibers, like frayed insulation on electrical wires, disrupting signals between the brain and body. Investors care because treatments, clinical trial results, regulatory approvals, and long-term care costs linked to the disease can materially affect the financial prospects of drugmakers, medical-device companies, and healthcare service providers.

mitochondrial medical

"company focused on improving mitochondrial health and protecting neuronal function"

Relating to mitochondria, the tiny structures inside cells that act like power plants to produce the energy cells need and help control cell survival. For investors this matters because problems with mitochondrial function are linked to certain diseases and are a focus for drugs, diagnostics and safety testing, so claims about “mitochondrial” effects can signal potential market opportunities or risks for healthcare-related companies.

neuronal medical

"improving mitochondrial health and protecting neuronal function to treat"

Relating to neurons, the specialized cells that carry signals in the brain and nervous system; think of neurons as the body's electrical wiring that sends messages between parts of the body and the brain. For investors, the term flags that a product, trial or risk involves the nervous system, which can mean large potential markets, complex safety and regulatory hurdles, and longer development timelines compared with non-neurological treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

Virtual Presentation Details
Date: January 21, 2026
Time of Presentation: 3:10 p.m. ET
Format: Corporate update

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1717095&tp_key=3c898db1bd&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.

About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Clene (CLNN) present at the Emerging Growth Conference?

Clene will present a corporate update on January 21, 2026 at 3:10 p.m. ET.

How can I watch the live Clene (CLNN) presentation on January 21, 2026?

You can register and view the live webcast via the provided registration link or watch from the Events section of Clene's website.

Will a replay of the Clene (CLNN) Emerging Growth presentation be available after the event?

Yes. A replay will be available through the conference portal and the Emerging Growth YouTube channel after the presentation.

What format will Clene's (CLNN) presentation follow at the Emerging Growth Conference?

The presentation format is a corporate update delivered via virtual webcast in Eastern Time.

Where is the Emerging Growth Conference webcast of Clene (CLNN) hosted after the event?

The replay will be hosted on the conference portal and on the Emerging Growth YouTube channel.

What topics will Clene (CLNN) management likely cover in the January 21, 2026 presentation?

The presentation is described as a corporate update; management is expected to discuss recent company developments and investor-relevant information.